BioCardia (BCDA) Net Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | -263.05% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.34 Bn | 55.72 Mn | -111.96% |
| 4 | Legend Biotech | 3.56 Bn | 2.60 Bn | 251.50 Mn | 114.92% |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.19 Bn | 1.40 Bn | 251.87 Mn | -61.56% |
| 9 | Vericel | 1.96 Bn | 1.80 Bn | 56.40 Mn | 1,842.32% |
| 10 | BioCardia | 13.18 Mn | 9.06 Mn | - | 10,112.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10,112.90% |
| Mar 31, 2026 | -8.65% |
| Dec 31, 2025 | -9.07% |
| Sep 30, 2025 | 22.74% |
| Jun 30, 2025 | -93.43% |
| Mar 31, 2025 | -823.38% |
| Dec 31, 2024 | -249.59% |
| Sep 30, 2024 | 242.06% |
| Jun 30, 2024 | 185.51% |
| Mar 31, 2024 | 93.85% |
| Dec 31, 2023 | -205.17% |
| Sep 30, 2023 | -26.86% |
| Jun 30, 2023 | 58.05% |
| Mar 31, 2023 | 14.82% |
| Dec 31, 2022 | 123.08% |
| Sep 30, 2022 | 26.67% |
| Jun 30, 2022 | 55.53% |
| Mar 31, 2022 | -3,196.84% |
| Dec 31, 2021 | -121.52% |
| Sep 30, 2021 | 28.13% |